Tag:
Adolor
Latest Headlines
Latest Headlines
Cubist Pharma strikes deal to buy Adolor for up to $415M
With its share price breaking through to a 52-week high, Cubist Pharmaceuticals ( $CBST ) has decided to beef up its pipeline of acute care products with a deal to buy Adolor Pharmaceuticals for $190
Pfizer opts out of $262M Adolor pain drug pact
Almost exactly three years after Pfizer ( $PFE ) put up $30 million and a promise of up to $232.5 million to partner on a pair of Adolor's pain programs, the pharma giant has opted to wash its hands of
Adolor cuts 30 jobs as Entereg sales falter
Exton, PA-based Adolor is cutting 30 jobs, or about a third of its workforce, as it attempts to reduce cash burn levels. The developer had 114 employees at the end of 2009. In May 2008, the FDA
Adolor shares sink after placebo effect scuttles PhIIa pain trial
Shares of Adolor ( ADLR ) took an 18 percent dive yesterday evening after the company announced that two of its pain meds partnered with Pfizer had failed a mid-stage clinical trial. Pfizer paid $30
FDA chastises Roche, Sanofi for drug promos
Another set of FDA letters is warning drugmakers off misleading promotions: This time, it's Roche, Sanofi-Aventis and Adolor that get the agency scolding for a multimedia array of promotions. The
Adolor inks $72M deal to in-license Lilly OBD drug
Adolor has plunked down $2 million upfront and committed to pay $70 million more in milestones for Eli Lilly's OpRA III, a clinical stage product being developed for opioid bowel dysfunction. Adolor
Adolor axes 45 workers and shifts clinical focus
Determined to cut its annual cash burn rate by $12 million a year, Adolor has opted to axe 45 jobs--28 percent of its workforce--as the developer shifts its focus away from early-stage clinical
Progenics, Wyeth drug fails late-stage trial
There's more bad news for Wyeth and Progenics Pharmaceuticals for their late-stage drug Relistor. Researchers say the drug failed to hit a primary endpoint in restoring gastrointestinal function
FDA finally gives thumbs-up to Entereg
GlaxoSmithKline and Adolor reached the Entereg summit. After a four-year climb, the two companies finally got FDA approval to sell the anti-constipation drug Entereg. It's OK'd for use after
FDA OKs Adolor's Entereg in first approval
Exton, PA-based Adolor hit a major milestone with the FDA's approval of Entereg for postoperative ileus, a common condition following surgery that can extend a patient's hospital stay. This is the
